{"entity":{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","aka":["Sino Biopharm","中国生物制药","Chia Tai Tianqing","CTTQ","Chia Tai Tianqing Pharmaceutical","Nanjing Shunxin Pharmaceutical","Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical"],"tldr":"Sino Biopharm, through Chia Tai Tianqing, sells anlotinib, one of China's biggest cancer drugs, and acquired LaNova Medicines to add bispecific antibodies and ADCs.","summary":"Anlotinib (Focus V) approved 2018 across lung cancer, sarcoma and thyroid cancer; the PD-L1 antibody benmelstobart (TQB2450) approved 2024 for small cell lung cancer with anlotinib; a large hepatitis and oncology generics franchise. In 2025 it agreed to acquire LaNova Medicines, whose PD-1 x VEGF bispecific LM-299 had been licensed to Merck & Co. in 2024, for up to about $951 million, an example of Chinese pharma buying Chinese biotech.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Sino_Biopharmaceutical_Limited","links":[{"label":"Official website (archived copy)","url":"https://web.archive.org/web/20251122085435/https://www.sinobiopharm.com/en/"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy","immunotherapy"],"technologies":[],"targets":[],"drugs":["anlotinib","tqb3702","tqb3909","tqb2868","benmelstobart"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04854668","nct06300177","nct05862337","nct06829771","nct05913089","nct06496490","nct07044908","nct06202261","nct07512583","nct06702618","nct06431490","nct07548177","nct06962267","nct07047365","nct06821503","nct07367516","nct06452706","nct06825494","nct07367529","nct06198751"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hong Kong / Nanjing","country":"CN","companyType":"pharma","website":"https://www.sinobiopharm.com","ticker":"1177.HK","investors":[],"funding":[]},"route":"/companies/sino-biopharm/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"al2846","kind":"drug","name":"AL2846","route":"/drugs/al2846/"},{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"},{"id":"benmelstobart","kind":"drug","name":"Benmelstobart","route":"/drugs/benmelstobart/"},{"id":"lm-108","kind":"drug","name":"LM-108","route":"/drugs/lm-108/"},{"id":"lm-302","kind":"drug","name":"LM-302","route":"/drugs/lm-302/"},{"id":"tq-b3234","kind":"drug","name":"TQ-B3234","route":"/drugs/tq-b3234/"},{"id":"tqb2102","kind":"drug","name":"TQB2102","route":"/drugs/tqb2102/"},{"id":"tqb2450","kind":"drug","name":"TQB2450","route":"/drugs/tqb2450/"},{"id":"tqb2825","kind":"drug","name":"TQB2825","route":"/drugs/tqb2825/"},{"id":"tqb2868","kind":"drug","name":"TQB2868","route":"/drugs/tqb2868/"},{"id":"tqb2922","kind":"drug","name":"TQB2922","route":"/drugs/tqb2922/"},{"id":"tqb2930","kind":"drug","name":"TQB2930","route":"/drugs/tqb2930/"},{"id":"tqb3454","kind":"drug","name":"TQB3454","route":"/drugs/tqb3454/"},{"id":"tqb3616","kind":"drug","name":"TQB3616","route":"/drugs/tqb3616/"},{"id":"tqb3702","kind":"drug","name":"TQB3702","route":"/drugs/tqb3702/"},{"id":"tqb3909","kind":"drug","name":"TQB3909","route":"/drugs/tqb3909/"},{"id":"tqb6411","kind":"drug","name":"TQB6411","route":"/drugs/tqb6411/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}],"trial":[{"id":"nct07043725","kind":"trial","name":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","route":"/trials/nct07043725/"},{"id":"nct07003074","kind":"trial","name":"A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct07003074/"},{"id":"nct06469879","kind":"trial","name":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","route":"/trials/nct06469879/"},{"id":"nct05913089","kind":"trial","name":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","route":"/trials/nct05913089/"},{"id":"nct05987358","kind":"trial","name":"A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma","route":"/trials/nct05987358/"},{"id":"nct06962267","kind":"trial","name":"A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)","route":"/trials/nct06962267/"},{"id":"nct07483684","kind":"trial","name":"A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxal","route":"/trials/nct07483684/"},{"id":"nct06566586","kind":"trial","name":"A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma","route":"/trials/nct06566586/"},{"id":"nct07653685","kind":"trial","name":"A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advan","route":"/trials/nct07653685/"},{"id":"nct06496490","kind":"trial","name":"A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality","route":"/trials/nct06496490/"},{"id":"nct06561607","kind":"trial","name":"A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","route":"/trials/nct06561607/"},{"id":"nct07011186","kind":"trial","name":"A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies","route":"/trials/nct07011186/"},{"id":"nct07367529","kind":"trial","name":"A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection","route":"/trials/nct07367529/"},{"id":"nct07815223","kind":"trial","name":"A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC","route":"/trials/nct07815223/"},{"id":"nct06860971","kind":"trial","name":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","route":"/trials/nct06860971/"},{"id":"nct04854668","kind":"trial","name":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Can","route":"/trials/nct04854668/"},{"id":"nct07538271","kind":"trial","name":"A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07538271/"},{"id":"nct06198751","kind":"trial","name":"A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","route":"/trials/nct06198751/"},{"id":"nct06431490","kind":"trial","name":"A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer","route":"/trials/nct06431490/"},{"id":"nct04523272","kind":"trial","name":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","route":"/trials/nct04523272/"},{"id":"nct06202261","kind":"trial","name":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer","route":"/trials/nct06202261/"},{"id":"alter-0303","kind":"trial","name":"ALTER 0303","route":"/trials/alter-0303/"},{"id":"nct05862337","kind":"trial","name":"Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.","route":"/trials/nct05862337/"},{"id":"nct06825494","kind":"trial","name":"Clinical Studies for the Treatment of Advanced Solid Tumors","route":"/trials/nct06825494/"},{"id":"nct07512583","kind":"trial","name":"Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors","route":"/trials/nct07512583/"},{"id":"nct06821503","kind":"trial","name":"Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","route":"/trials/nct06821503/"},{"id":"nct06767813","kind":"trial","name":"Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms","route":"/trials/nct06767813/"},{"id":"nct05780567","kind":"trial","name":"Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer","route":"/trials/nct05780567/"},{"id":"nct07385703","kind":"trial","name":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct07385703/"},{"id":"nct07367516","kind":"trial","name":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","route":"/trials/nct07367516/"},{"id":"nct07008976","kind":"trial","name":"Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer","route":"/trials/nct07008976/"},{"id":"nct06829771","kind":"trial","name":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","route":"/trials/nct06829771/"},{"id":"nct06854445","kind":"trial","name":"Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma","route":"/trials/nct06854445/"},{"id":"nct07548177","kind":"trial","name":"Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma","route":"/trials/nct07548177/"},{"id":"nct06300177","kind":"trial","name":"D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standar","route":"/trials/nct06300177/"},{"id":"nct07545213","kind":"trial","name":"Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis","route":"/trials/nct07545213/"},{"id":"nct07407803","kind":"trial","name":"Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas","route":"/trials/nct07407803/"},{"id":"nct06702618","kind":"trial","name":"Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer","route":"/trials/nct06702618/"},{"id":"nct07294261","kind":"trial","name":"Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC","route":"/trials/nct07294261/"},{"id":"nct04846634","kind":"trial","name":"Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (A","route":"/trials/nct04846634/"},{"id":"nct07501169","kind":"trial","name":"Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","route":"/trials/nct07501169/"},{"id":"nct05576480","kind":"trial","name":"SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer","route":"/trials/nct05576480/"},{"id":"nct06452706","kind":"trial","name":"The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer","route":"/trials/nct06452706/"},{"id":"nct05365178","kind":"trial","name":"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer","route":"/trials/nct05365178/"},{"id":"nct07044908","kind":"trial","name":"TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer","route":"/trials/nct07044908/"},{"id":"nct07047365","kind":"trial","name":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","route":"/trials/nct07047365/"},{"id":"nct06456138","kind":"trial","name":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC","route":"/trials/nct06456138/"}]}}